Clinical Trials Logo

Central Hypothyroidism clinical trials

View clinical trials related to Central Hypothyroidism.

Filter by:
  • None
  • Page 1

NCT ID: NCT05752591 Completed - Hypogonadism Clinical Trials

Hypothalamic-pituitary Dysfunction in Diabetes

DIAPO
Start date: May 25, 2018
Phase:
Study type: Observational

Type 2 Diabetes mellitus (T2DM) is a chronic disease with a high prevalence and several comorbidities impacting on public health and society. Among the complications of T2DM it has been showed a high prevalence of hypogonadotropic hypogonadism. Even if hypogonadism is associated to a worse metabolic profile and cardiovascular risk, it is discussed whether and when to treat this potentially reversible form associated to diabetes. In fact, the pathogenic mechanism of this condition in diabetic patients is not fully understood, and its clinical correlates, including the prevalence of other possible associated hypothalamic-pituitary axes dysfunctioning, questioned. The aim of the present study is to assess with an observational, cross sectional study on a large series of type 2 diabetic patients, enrolled consecutively: all the suspected etiologies of this complication in one single evaluation (both acquired and genetic congenital predisposition), its clinical correlates and the real prevalence of the disease using the lastly validated criteria for late onset hypogonadotropic hypogonadism.

NCT ID: NCT03823859 Completed - Hypothyroidism Clinical Trials

Metabolomics of Thyroid Hormones

MATcH
Start date: December 12, 2018
Phase:
Study type: Observational [Patient Registry]

The aim of this study is to develop a metabolome signature of thyroid hormone status. The metabolome signature could be useful in diagnosis and treatment of thyroid dysfunction diseases, especially in cases where TSH cannot be reliably used.

NCT ID: NCT01280292 Enrolling by invitation - Clinical trials for Central Hypothyroidism

Central Hypothyroidism, a Novel Laboratory Measurement

Start date: February 2011
Phase: N/A
Study type: Interventional

Medical management of central hypothyroidism is controversial due to lack of reference for evaluation of pituitary negative feedback. Therefore, titration of medical treatment is based on T4 levels, measured with variable laboratory methods. Patients who have central hypothyroidism usually have concomitant deficiencies in other pituitary hormones for which they need replacement therapy such as steroids, testosterone and growth hormone. This combined hormone deficiency makes clinical and laboratory evaluation challenging among these patients. Symptomatically, central hypothyroidism is relatively mild and lack non-specific and it might be overlooked due to other hormonal deficiencies. Replacement therapy for central hypothyroidism is titrated by arbitrary target free T4 levels of above 50th percentile of normal. The goal of our study is to compare the standard results from well known measure methods to a new method for measuring Ft4 using Liquid chromatography - tandem mass spectrometry.